Philip James Wealth Mangement LLC Sells 10,845 Shares of Solventum Corporation $SOLV

Philip James Wealth Mangement LLC reduced its stake in shares of Solventum Corporation (NYSE:SOLV) by 25.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,480 shares of the company’s stock after selling 10,845 shares during the quarter. Philip James Wealth Mangement LLC’s holdings in Solventum were worth $2,298,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its position in Solventum by 0.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 33,974 shares of the company’s stock worth $2,577,000 after purchasing an additional 210 shares during the last quarter. South Dakota Investment Council increased its stake in shares of Solventum by 3.6% in the 2nd quarter. South Dakota Investment Council now owns 255,625 shares of the company’s stock valued at $19,387,000 after buying an additional 8,960 shares during the period. Chelsea Counsel Co. raised its position in shares of Solventum by 720.7% during the second quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock worth $804,000 after acquiring an additional 9,304 shares during the last quarter. Purus Wealth Management LLC bought a new stake in shares of Solventum during the second quarter worth $252,000. Finally, ST Germain D J Co. Inc. lifted its stake in shares of Solventum by 84.6% during the second quarter. ST Germain D J Co. Inc. now owns 825 shares of the company’s stock valued at $63,000 after acquiring an additional 378 shares during the period.

Solventum Stock Up 0.4%

Shares of NYSE SOLV opened at $86.12 on Friday. The stock has a market cap of $14.94 billion, a P/E ratio of 9.92, a P/E/G ratio of 8.57 and a beta of 0.34. The firm has a 50 day moving average price of $79.82 and a 200 day moving average price of $75.44. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. Solventum Corporation has a 52-week low of $60.70 and a 52-week high of $88.20.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The company had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.05 billion. During the same period last year, the firm posted $1.64 earnings per share. The business’s quarterly revenue was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Solventum announced that its board has approved a share buyback program on Thursday, November 20th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 7.5% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

Several analysts have weighed in on SOLV shares. BTIG Research raised Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Tuesday, December 2nd. Stifel Nicolaus lifted their price target on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday. UBS Group restated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research report on Thursday, October 30th. Five research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $88.64.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.